This advisory will remain in effect until the product is fully compliant to the regulations of the FDA and issued with a CPN
Mounjaro and Zepbound (tirzepatide) growing fastest (CAGR)
Great site she customer service
For weight management, at least 5% weight loss from baseline after 12 weeks on maintenance dose is required to continue treatment
doi: 10.1159/000492853 66 LuuMWeigandKWediFBreidenbendCLeisterHPautzSet al
Large, long-term outcome studies show that GLP-1 therapies improve outcomes and reduce the incidence of diseases closely linked to inflammation, including osteoarthritis, cardiovascular disease, fatty liver disease, chronic kidney disease, Alzheimers, and autoimmune conditions